Fibrinolytic composition and method of its preparation
US12226462B2 · kind B2 · utility
0Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2020 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Oct 3, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21007
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses modified forms of plasmin with advantageous properties. As compared to their natural unmodified form, these variants exhibit significantly modulated kinetics in terms of delayed inhibition characteristics in the presence of specific inhibitors, such as α2-antiplasmin (α2-AP). These include PEG-conjugated thiol derivatives of truncated plasmin with potential clinical applications in various regimens of thrombolytic therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.